Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo New Product Introductions Drive OTC Growth In Fiscal 1999

This article was originally published in The Tan Sheet

Executive Summary

Perrigo achieved "modest" gains in the OTC category in the fiscal year ended July 3, the firm reported Aug. 26. "New products contributed to growth, and we are pleased with the progress of ibuprofen suspension, pseudoephedrine extended-release tablets, the miconazole 3 combination package and a nicotine patch for smoking cessation," the Allegan, Mich.-based private labeler said.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel